Granata Bio has acquired Oviva Therapeutics, a women’s health biotech company focused on treatments addressing female physiology and ovarian aging.
Oviva’s lead candidate, OVI-586, is described as a first-in-class therapeutic designed to extend ovarian function, which could potentially address key women’s health challenges since the ovaries are typically the first organ to decline with age. The therapeutic has potential applications in menopause, contraception, and in vitro fertilization (IVF).
“At Granata Bio, our mission is to identify and develop innovative solutions for fertility patients. The acquisition of Oviva Therapeutics marks a significant milestone in our efforts to bring forward new therapies for those with limited treatment options. In IVF stimulation, OVI-586 offers a biologically grounded approach to improving ovarian response— even in patients with diminished ovarian reserve. We’re excited to continue advancing OVI-586 and explore its potential in assisted reproductive technology (ART) and beyond,” said Evan Sussman, Co-Founder and CEO of Granata Bio.
James Peyer, Founder and CEO of Cambrian BioPharma, which partnered with Oviva’s founding team, stated: “This is a big day for women’s health. Cambrian partnered with Drs. Daisy Robinton, David Pepin, and Pat Donahue to found Oviva and develop the first truly novel mechanism in women’s health in the last 50 years. We’re thrilled about this acquisition and looking forward to seeing Oviva’s OVI-586 progress to the next stage of development under Granata’s leadership. This transaction reflects the importance of Cambrian’s objective: identify amazing scientific discoveries and turn those discoveries into great businesses.”
The acquisition comes just three months after Granata Bio raised $15 million in Series A+ funding in January 2025. That round was supported exclusively by existing investors, including women’s health leaders Gedeon Richter and CooperSurgical, along with Amboy Street Ventures and other strategic investors, bringing the company’s total funding to over $30 million at the time.
Founded in 2018, Granata Bio is targeting the $3.6 billion global infertility medication market and describes itself as dedicated to advancing innovation in women’s health and infertility, with a pipeline that includes various fertility therapies and collaborations across multiple IVF product classes. Oviva Therapeutics focuses on improving women’s experience of aging through biomedical research, development and advocacy.
Financial details of the acquisition were not disclosed.
